[Ip-health] ‘NTD Drug Discovery Booster’ Experiment Launched by DNDi with Four Pharmaceutical Companies
glandry at dndi.org
Fri May 29 01:20:54 PDT 2015
Yesterday we launched a drug discovery ‘experiment’ by which DNDi and four pharmaceutical companies will work together to reduce time and cost of a very early stage of the drug discovery process for new treatments for Chagas disease and Leishmaniasis. It is the first time that we work on one project with several companies at one time, screening entire compound libraries and with all companies agreeing not to pose IP barriers and agreeing that if there is a compound that is taken further into the drug development process - no matter which company the compound comes from - the consortium as a whole is credited. Here below is the press release (also here http://www.dndi.org/media-centre/press-releases/2156-pr-drug-discovery-booster.html). You can also find a short animated film about the booster on this page: http://www.dndi.org/drugdiscoverybooster
DNDi and Four Pharmaceutical Companies Announce ‘Drug Discovery Booster’ Experiment to Accelerate and Expand Discovery of New Drugs for Two Highly Neglected Diseases – Leishmaniasis and Chagas disease
*First multi-company engagement in a single project with DNDi to tackle neglected tropical diseases, supported by the Japanese Global Health Innovative Technology Fund
The Drugs for Neglected Diseases initiative (DNDi) and four pharmaceutical firms, Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca plc have announced the start of a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease. The ‘Neglected Tropical Diseases Drug Discovery Booster’ consortium, through a carefully engineered modus operandi, will circumvent early stage commercial barriers between the four pharmaceutical participants, allowing DNDi, for the first time, to search millions of unique compounds simultaneously, in the hunt for new treatment leads for leishmaniasis and Chagas disease.
‘This experimental approach to radically modernize drug development for neglected diseases is the result of a decade of growing partnerships with pharmaceutical companies’, said Dr Bernard Pécoul, Executive Director of DNDi. ‘This experiment could significantly reduce the time and money it takes to find new, promising treatment leads, and echoes the great potential of innovative research and development collaborations.’
Traditionally, early stage drug discovery to find new treatments has been an expensive and time-consuming process. To identify promising new compounds for neglected diseases, DNDi has worked bilaterally with a range of pharmaceutical partners, searching through segments of their vast compound libraries, and testing them against infected cells. The Drug Discovery Booster is a new approach, using a multilateral, simultaneous search process across participating companies, thus allowing DNDi access to compounds generated over many decades of research. State-of-the-art technology will be used to pinpoint compounds that have promising characteristics for further testing.
The innovation of the Drug Discovery Booster not only lies in the multilateral approach, but also in the iterative nature of the search, meaning companies will continually examine their libraries for better matches as the search is refined. The Drug Discovery Booster has the potential to cut up to two years from the early drug discovery process, which takes approximately five years or more, and improve cost-efficiency across research activities.
The new process starts with DNDi providing all four companies with a common chemical starting point, the ‘seed’ compound. This compound will have shown promising results against Leishmania or Trypanosoma cruzi, the parasites that cause leishmaniasis and Chagas disease, but may not yet be optimal for use as a future treatment. The four companies will then search their own full collections of high-quality chemical compounds for similar and potentially better molecules, and will select and send the most promising to DNDi, which will then have them screened for potential effectiveness against these two deadly parasitic diseases. The aim is to continually improve the effectiveness of the compounds.
DNDi will then select the best ‘hits’ for further testing. This process will be repeated up to three times, with each new iteration – or round – starting from an improved seed compound identified from within one of the four partner’s collections and shared with all. The initial project goal is to explore the consortium’s compound libraries for at least four promising seed compounds for each disease. It is expected that at least two of the resulting novel series of compounds will move to the next stage of development towards a new medicine.
Any progress or successful new treatment for leishmaniasis or Chagas disease resulting from the Drug Discovery Booster will be attributed to the collective effort of all partners, which have also agreed that no intellectual property barriers will be imposed to a new treatment if successful.
The GHIT Fund, launched in 2013, stimulates and supports such international global health research and development partnerships. Through a grant of EUR 640,000 or 79.5 million Japanese Yen provided to DNDi, GHIT will support the involvement of the three Japanese companies in this project. The remainder of the project, including the involvement of AstraZeneca plc, is being supported by DNDi core funds.
‘The Drug Discovery Booster could be a game-changing milestone in the fight against diseases that destroy the health and livelihoods of the world’s poorest’, said Dr BT Slingsby, GHIT Fund CEO. ‘Industry’s innovative leadership for the most neglected of the neglected diseases will be essential to accelerate progress toward creating life-saving medicines, and GHIT is proud to support the important contribution of Japanese pharmaceutical companies to make this possible.’
Sian Bowen, DNDi Communications Manager (Geneva) + 41 79 932 4268
Ilan Moss, DNDi Communications Manager (New York) + 1 646 266 5216
Gabrielle Landry Chappuis, M.A. | Head of Communication and Advocacy
Drugs for Neglected Diseases initiative
15 Chemin Louis-Dunant | 1202 Geneva | Switzerland
T: +41 22 906 92 49 | M: +41 79 309 39 10 | glandry at dndi.org<mailto:glandry at dndi.org> | skype: dndi_gabrielle.landry
Best Science for the Most Neglected | www.dndi.org<http://www.dndi.org/>
More information about the Ip-health